Frontage Holdings Corporation (HKG:1521)
Hong Kong · Delayed Price · Currency is HKD 1.140
0.00 (0.00%)
At close: Mar 27, 2026
Frontage Holdings Market Cap
Frontage Holdings has a market cap or net worth of 2.31 billion as of March 27, 2026. Its market cap has increased by 3.85% in one year.
Market Cap
2.31B
Enterprise Value
3.14B
Revenue
1.99B
Ranking
n/a
PE Ratio
76.72
Stock Price
1.14
Market Cap Chart
Since May 30, 2019, Frontage Holdings's market cap has decreased from 6.73B to 2.31B, a decrease of -65.63%. That is a compound annual growth rate of -14.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 2.31B | 14.00% |
| Dec 31, 2025 | 2.03B | -43.71% |
| Dec 31, 2024 | 3.60B | -23.57% |
| Dec 29, 2023 | 4.71B | -20.20% |
| Dec 30, 2022 | 5.91B | -27.11% |
| Dec 31, 2021 | 8.10B | -6.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 30, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Antengene Corporation | 3.28B |
| Medtide | 3.18B |
| Jiangsu Recbio Technology | 2.52B |
| SinoMab BioScience | 2.45B |
| Mabpharm | 2.27B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.92B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.87B |
| Cutia Therapeutics | 1.73B |